1 / 3

SWITCHMRK: Switching From Lopinavir/Ritonavir to Raltegravir

SWITCHMRK: Switching From Lopinavir/Ritonavir to Raltegravir. 2 randomized, double-blind studies SWITCHMRK 1 (n=348): European Union, Australia, North America SWITCHMRK 2 (n=354): Australia, North/Latin America, Africa, Southeast Asia Patients

azana
Download Presentation

SWITCHMRK: Switching From Lopinavir/Ritonavir to Raltegravir

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SWITCHMRK: Switching From Lopinavir/Ritonavir to Raltegravir • 2 randomized, double-blind studies • SWITCHMRK 1 (n=348): European Union, Australia, North America • SWITCHMRK 2 (n=354): Australia, North/Latin America, Africa, Southeast Asia • Patients • Well-controlled patients on lopinavir/r bid + >2 NRTIs (and no other active PI) • No lipid lowering therapy for at least 12 weeks • Randomized groups • Continue lopinavir/r-based regimen • Switch to raltegravir + background antiretroviral regimen • Primary endpoints • Week 12: percent change in lipids • Week 24: proportion of patients with HIV RNA <50 copies/mL • Non-inferiority: +12% Eron J, et al. 16th CROI. Montreal, 2009. Abstract 70aLB.

  2. SWITCHMRK:Week-24 Outcomes HIV RNA <50 Copies/mL CD4 Cell Change Raltegravir LPV/r Raltegravir LPV/r 94% 88% 87% 81% 17 CD4 Cell Change (cells/mm3) Patients (%) 7 5 5 SWITCHMRK 2 SWITCHMRK 1 SWITCHMRK 2 SWITCHMRK 1 HIV RNA <50 copies/mL: did not meet non-inferiority criteria. Eron J, et al. 16th CROI. Montreal, 2009. Abstract 70aLB.

  3. SWITCHMRK:Week-12 Lipid Changes *P<0.001 versus LPV/r within each study. Eron J, et al. 16th CROI. Montreal, 2009. Abstract 70aLB.

More Related